Emcure Cuts Obesity Drug Prices Amid Rising Health Burden in India

In a move aimed at tackling India’s growing obesity crisis, Emcure Pharmaceuticals Ltd. has reduced the price of its semaglutide-based drug Poviztra® by up to 55%.

The revised pricing will see the starting dose (0.25 mg) available at Rs. 3,999 per month, significantly lower than its earlier price. Overall, prices across doses have been reduced by an average of 47%.

The drug, administered once weekly via a pen device, is backed by extensive global clinical evidence and has been widely used for weight management.

India is witnessing a sharp rise in obesity-related conditions, including diabetes, cardiovascular diseases, and hypertension. The company said the price cut is expected to make advanced treatment more accessible to a wider patient base.

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, “The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity.3 Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.”